
Annual report 2025
added 02-24-2026
Orthofix Medical Revenue 2011-2026 | OFIX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Orthofix Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 822 M | 799 M | 747 M | 461 M | 464 M | 407 M | 460 M | 453 M | 434 M | 410 M | 396 M | 402 M | 401 M | 462 M | 579 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 822 M | 396 M | 513 M |
Quarterly Revenue Orthofix Medical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 206 M | 203 M | 194 M | - | 197 M | 199 M | 189 M | - | 184 M | 187 M | 175 M | - | 114 M | 118 M | 106 M | - | 112 M | 121 M | 106 M | - | 111 M | 73.1 M | 105 M | 121 M | 113 M | 116 M | 109 M | 121 M | 112 M | 112 M | 109 M | 117 M | 105 M | 109 M | 103 M | 109 M | 98.5 M | 104 M | 98.7 M | 105 M | 101 M | 101 M | 89.8 M | 100 M | 101 M | 101 M | 100 M | 106 M | 91.8 M | 97.6 M | 103 M | 116 M | 108 M | 113 M | 116 M | 119 M | 117 M | 117 M | 139 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 206 M | 73.1 M | 122 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
4 B | $ 176.83 | 5.97 % | $ 13.2 B | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 11.66 | 5.71 % | $ 1.75 B | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
AxoGen
AXGN
|
225 M | $ 34.0 | 9.71 % | $ 1.57 B | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.18 | 2.01 % | $ 1.65 B | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 281.15 | 1.13 % | $ 7.93 B | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 38.25 | 4.31 % | $ 5.7 K | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 62.56 | 1.15 % | $ 92.6 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Electromed
ELMD
|
64 M | $ 24.4 | 2.61 % | $ 206 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 9.17 | 1.1 % | $ 260 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 91.96 | 2.13 % | $ 12.4 B | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.14 | 2.22 % | $ 876 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Nevro Corp.
NVRO
|
409 M | - | - | $ 217 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.62 | 1.67 % | $ 38.6 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.37 | -0.88 % | $ 126 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.85 | 1.86 % | $ 353 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 36.59 | 5.94 % | $ 1.14 B | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.62 | 0.22 % | $ 122 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 81.71 | 1.08 % | $ 47.8 B | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 53.38 | -1.89 % | $ 1.57 B | ||
|
Varex Imaging Corporation
VREX
|
845 M | $ 11.04 | 4.25 % | $ 457 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.88 | 2.73 % | $ 1.14 M | ||
|
Inogen
INGN
|
349 M | $ 6.67 | -1.91 % | $ 177 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.03 | - | $ 17.4 M | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 87.48 | 2.78 % | $ 3.04 B | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 16.01 | 1.59 % | $ 376 M |